134 related articles for article (PubMed ID: 37369013)
21. Head pleomorphic sarcoma showing murine double minute 2 amplification without a well-differentiated liposarcoma component in a pediatric patient.
Akaihata M; Takahashi I; Kakuda Y; Kawata T; Mukaigawa T; Onitsuka T; Murayama S; Ishida Y
Cancer Rep (Hoboken); 2023 Feb; 6(2):e1774. PubMed ID: 36572546
[TBL] [Abstract][Full Text] [Related]
22. Vanished MDM2 amplification in multiple recurrences of an irradiated poorly differentiated sarcoma with amplified TRIO::TERT fusion gene.
Goffinet S; Di Mauro I; Doyen J; Boyer J; Birtwisle-Peyrottes I; Keslair F; Pedeutour F; Dadone-Montaudie B
Genes Chromosomes Cancer; 2023 Jun; 62(6):342-352. PubMed ID: 36916207
[TBL] [Abstract][Full Text] [Related]
23. Model-based assessments of CYP3A-mediated drug-drug interaction risk of milademetan.
Hong Y; Ishizuka T; Watanabe A; Tachibana M; Lee M; Ishizuka H; LaCreta F; Abutarif M
Clin Transl Sci; 2021 Nov; 14(6):2220-2230. PubMed ID: 34080309
[TBL] [Abstract][Full Text] [Related]
24. Intimal sarcoma is the most frequent primary cardiac sarcoma: clinicopathologic and molecular retrospective analysis of 100 primary cardiac sarcomas.
Neuville A; Collin F; Bruneval P; Parrens M; Thivolet F; Gomez-Brouchet A; Terrier P; de Montpreville VT; Le Gall F; Hostein I; Lagarde P; Chibon F; Coindre JM
Am J Surg Pathol; 2014 Apr; 38(4):461-9. PubMed ID: 24625414
[TBL] [Abstract][Full Text] [Related]
25. Amplification of the MDM2 gene, but not expression of splice variants of MDM2 MRNA, is associated with prognosis in soft tissue sarcoma.
Bartel F; Meye A; Würl P; Kappler M; Bache M; Lautenschläger C; Grünbaum U; Schmidt H; Taubert H
Int J Cancer; 2001 May; 95(3):168-75. PubMed ID: 11307150
[TBL] [Abstract][Full Text] [Related]
26. Are peripheral purely undifferentiated pleomorphic sarcomas with MDM2 amplification dedifferentiated liposarcomas?
Le Guellec S; Chibon F; Ouali M; Perot G; Decouvelaere AV; Robin YM; Larousserie F; Terrier P; Coindre JM; Neuville A
Am J Surg Pathol; 2014 Mar; 38(3):293-304. PubMed ID: 24525499
[TBL] [Abstract][Full Text] [Related]
27. Resistance mechanisms to TP53-MDM2 inhibition identified by in vivo piggyBac transposon mutagenesis screen in an Arf
Chapeau EA; Gembarska A; Durand EY; Mandon E; Estadieu C; Romanet V; Wiesmann M; Tiedt R; Lehar J; de Weck A; Rad R; Barys L; Jeay S; Ferretti S; Kauffmann A; Sutter E; Grevot A; Moulin P; Murakami M; Sellers WR; Hofmann F; Jensen MR
Proc Natl Acad Sci U S A; 2017 Mar; 114(12):3151-3156. PubMed ID: 28265066
[TBL] [Abstract][Full Text] [Related]
28. Separate amplified regions encompassing CDK4 and MDM2 in human sarcomas.
Berner JM; Forus A; Elkahloun A; Meltzer PS; Fodstad O; Myklebost O
Genes Chromosomes Cancer; 1996 Dec; 17(4):254-9. PubMed ID: 8946207
[TBL] [Abstract][Full Text] [Related]
29. Phase I dose-escalation study of milademetan in patients with relapsed or refractory acute myeloid leukemia.
Sekiguchi N; Kasahara S; Miyamoto T; Kiguchi T; Ohno H; Takagi T; Tachibana M; Sumi H; Kakurai Y; Yamashita T; Usuki K
Int J Hematol; 2023 Jan; 117(1):68-77. PubMed ID: 36258088
[TBL] [Abstract][Full Text] [Related]
30. Gains of 12q13-14 and overexpression of mdm2 are frequent findings in intimal sarcomas of the pulmonary artery.
Bode-Lesniewska B; Zhao J; Speel EJ; Biraima AM; Turina M; Komminoth P; Heitz PU
Virchows Arch; 2001 Jan; 438(1):57-65. PubMed ID: 11213836
[TBL] [Abstract][Full Text] [Related]
31. Primary Cardiac Intimal Sarcoma: Multi-Layered Strategy and Core Role of
Nistor C; Carsote M; Cucu AP; Stanciu M; Popa FL; Ciuche A; Ciobica ML
Diagnostics (Basel); 2024 Apr; 14(9):. PubMed ID: 38732333
[TBL] [Abstract][Full Text] [Related]
32. Degree of
Bill KLJ; Seligson ND; Hays JL; Awasthi A; Demoret B; Stets CW; Duggan MC; Bupathi M; Brock GN; Millis SZ; Shakya R; Timmers CD; Wakely PE; Pollock RE; Chen JL
Oncologist; 2019 Jul; 24(7):989-996. PubMed ID: 31019022
[TBL] [Abstract][Full Text] [Related]
33. MDM2/X inhibitors under clinical evaluation: perspectives for the management of hematological malignancies and pediatric cancer.
Tisato V; Voltan R; Gonelli A; Secchiero P; Zauli G
J Hematol Oncol; 2017 Jul; 10(1):133. PubMed ID: 28673313
[TBL] [Abstract][Full Text] [Related]
34. RG7112, a small-molecule inhibitor of MDM2, enhances trabectedin response in soft tissue sarcomas.
Obrador-Hevia A; Martinez-Font E; Felipe-Abrio I; Calabuig-Fariñas S; Serra-Sitjar M; López-Guerrero JA; Ramos R; Alemany R; Martín-Broto J
Cancer Invest; 2015; 33(9):440-50. PubMed ID: 26288114
[TBL] [Abstract][Full Text] [Related]
35. [Molecular biology of soft-tissue sarcomas].
Coindre JM
Bull Cancer; 2010 Nov; 97(11):1337-45. PubMed ID: 21084242
[TBL] [Abstract][Full Text] [Related]
36. MDM2 overexpression is rare in ovarian carcinoma irrespective of TP53 mutation status.
Foulkes WD; Stamp GW; Afzal S; Lalani N; McFarlane CP; Trowsdale J; Campbell IG
Br J Cancer; 1995 Oct; 72(4):883-8. PubMed ID: 7547235
[TBL] [Abstract][Full Text] [Related]
37. Amplification of the CDK4 gene in sarcomas: tumor specificity and relationship with the RB gene mutation.
Kanoe H; Nakayama T; Murakami H; Hosaka T; Yamamoto H; Nakashima Y; Tsuboyama T; Nakamura T; Sasaki MS; Toguchida J
Anticancer Res; 1998; 18(4A):2317-21. PubMed ID: 9703873
[TBL] [Abstract][Full Text] [Related]
38. Rare MDM4 gene amplification in colorectal cancer: The principle of a mutually exclusive relationship between MDM alteration and TP53 inactivation is not applicable.
Suda T; Yoshihara M; Nakamura Y; Sekiguchi H; Godai TI; Sugano N; Tsuchida K; Shiozawa M; Sakuma Y; Tsuchiya E; Kameda Y; Akaike M; Matsukuma S; Miyagi Y
Oncol Rep; 2011 Jul; 26(1):49-54. PubMed ID: 21503588
[TBL] [Abstract][Full Text] [Related]
39. Targeted Brain Tumor Therapy by Inhibiting the MDM2 Oncogene: In Vitro and In Vivo Antitumor Activity and Mechanism of Action.
Punganuru SR; Artula V; Zhao W; Rajaei M; Deokar H; Zhang R; Buolamwini JK; Srivenugopal KS; Wang W
Cells; 2020 Jul; 9(7):. PubMed ID: 32630235
[TBL] [Abstract][Full Text] [Related]
40. MDM2 Amplification in Intrahepatic Cholangiocarcinomas: Its Relationship With Large-Duct Type Morphology and Uncommon KRAS Mutations.
Kim SJ; Akita M; Sung YN; Fujikura K; Lee JH; Hwang S; Yu E; Otani K; Hong SM; Zen Y
Am J Surg Pathol; 2018 Apr; 42(4):512-521. PubMed ID: 29309301
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
